ZELLUNA ASA
996713008ActivePioneering TCR-NK cell therapies to eliminate solid cancers effectively.
Yleiskatsaus
- 7
- Työntekijät
- Tuntematon
- Liikevaihto
- 2011
- Perustettu
Avainpäättäjät
Namir Hassan
Chief Executive Officer
Geir Christian Melen
Chief Financial Officer
Luise Weigand
Chief Scientific Officer
Michael Nishimura
Scientific Advisory Board Member
+15 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Zelluna ASA is a biotechnology company focused on pioneering novel cell therapies for cancer treatment. Their primary mission is to eliminate solid cancers, which represent the largest cancer burden globally. They are developing a unique and proprietary TCR-NK (T cell receptor guided natural killer)...
Tunnisteet
Avainsanat
Teknologiat
Yritystiedot
- Toimiala
- Tuntematon
- Oikeudellinen muoto
- Allmennaksjeselskap
- ALV-numero
- Tuntematon
Päättäjät
19 yhteystietoa FunnelfeedrissäNamir Hassan
Chief Executive Officer
Geir Christian Melen
Chief Financial Officer
Luise Weigand
Chief Scientific Officer
Michael Nishimura
Scientific Advisory Board Member
Emilie Gauthy
Chief Technology Officer
Anders Holm
Chief Operating Officer and Head of Business Development
May Sabry
Scientific Advisory Board Member
Omid Hamid
Scientific Advisory Board Member
Eva-Lotta Allan
Board Member
Julia Ino
Head of Project Management
Bent Jakobsen
Board Member
Charlotte Sofie Bergsagel Berg-Svendsen
Board Member
Ulrike Köhl
Scientific Advisory Board Member
Øivind Foss
Head of Clinical Operations
Dirk Jäger
Scientific Advisory Board Member
Wolf Hervé Fridman
Scientific Advisory Board Member
Hans Ivar Robinson
Board Member
Joachim Midttun
Finance Manager
Muut yhteyshenkilöt
Anders Tuv
Advisor
Samankaltaiset yritykset
20 samankaltaista yritystä Funnelfeedrissä
Ultimovacs AB
0 työntekijätPioneering off-the-shelf TCR-NK cell therapies to cure solid cancers.
BIO INVENTION AS
Clinical-stage company developing novel immuno-oncology antibody therapeutics for cancer.
CuraCell TX AB
5 työntekijätEuropean biotech developing personalized T-cell therapies for solid cancer tumors.
CELLMOVER AS
6 työntekijätPre-clinical immunotherapy company optimizing immune cell targeting for cancer.
NUCLITHERA AS
9 työntekijätDeveloping targeted alpha and beta emitters for metastatic cancer treatment.
Selaa lisää
Kysymyksiä yrityksestä ZELLUNA ASA
Haluatko nähdä Funnelfeedrin toiminnassa?
Varaa ilmainen demo ja tutustu siihen, miten Funnelfeedr auttaa sinua löytämään ja konvertoimaan ihanteelliset asiakkaasi.
Varaa demo